Trial Profile

The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With Relapsed or Refractory B-lymphoblastic Leukemia

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CT RD06 (Primary)
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

01 Jun 2025 According to a Bioheng Therapeutics media release, results from this investigator-initiated trial (IIT) of RD06-03, were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
01 Jun 2025 Results presented in the Bioheng Therapeutics Media Release.
23 Jan 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com